Amgen Inc.

🇺🇸NASDAQ Global Select

Articles

57
Show Summary
Show Bulletpoints
Detailed View
Slightly Bullish +25

Morgan Stanley Keeps Their Hold Rating on Amgen (AMGN)

📊 Analysts maintain mixed ratings, with Morgan Stanley holding AMGN at $332.

💰 Q4 revenue hit $9.9B and net profit reached $1.33 billion.

📈 Fiscal 2026 EPS guidance ranges from $21.70 to $23.10.

🏗️ Company projects $2.6B in capital expenditures for fiscal 2026.

💸 Share repurchases are capped at $3 billion over the period.

📊 Morgan Stanley analyst Terence Flynn maintained a "Hold" rating on Amgen (AMGN) with a price target of $332.00.

💼 Flynn covers the Healthcare sector, including peers BioNTech and Biogen, with a historical success rate of 55.65%.

📉 Recently, Bernstein also issued a "Hold" rating on Amgen, while TD Cowen reiterated its "Buy" stance from April.

💰 Based on Q4 earnings ending December 31, Amgen reported quarterly revenue of $9.9 billion and net profit of $1.33 billion.

📈 Comparatively, the company earned $9.09 billion in revenue and $627 million in net profit for the same period last year.

⚖️ For fiscal 2026, Amgen raised its adjusted EPS view range to $21.70–$23.10 from the previous $21.60–$23.00.

📉 Q1 adjusted earnings per share came in at $5.15, beating the consensus estimate of $4.77.

🏗️ Amgen projects fiscal 2026 capital expenditures will total $2.6 billion.

💸 The company also plans that share repurchases will not exceed $3 billion over the period.

Bullish Signals
  • Amgen reported quarterly revenue of $9.9 billion, compared to $9.09 billion last year, showing strong sequential growth.
  • The company delivered a net profit of $1.33 billion versus $627 million in the prior year, more than doubling profitability.
  • Amgen raised its FY26 adjusted EPS view to $21.70-$23.10 from $21.60-$23.00, signaling management's increased confidence in future earnings growth.
  • Q1 adjusted EPS of $5.15 exceeded consensus estimates of $4.77, demonstrating strong operational performance.
  • Amgen plans share repurchases not to exceed $3 billion, which can support stock price and return value to shareholders.
  • TD Cowen reiterated a Buy rating on Amgen (NASDAQ: AMGN), indicating continued confidence in the stock's upside potential.
Risk Factors
  • Morgan Stanley maintained a Hold rating on Amgen (AMGN), signaling that the stock is currently underweight relative to its potential, with a price target of $332.00.
  • Amgen's previous year revenue and profit were significantly lower at $9.09 billion and $627 million respectively compared to the current quarter's figures, highlighting recent volatility or past weakness in financial performance.
  • Bernstein issued a Hold rating on April 21, while only TD Cowen maintained a Buy, indicating a split opinion among major analysts with cautious sentiment from Morgan Stanley and Bernstein.
  • Amgen raised its FY26 adjusted EPS view slightly to $21.70-$23.10 from $21.60-$23.00, which could imply that current growth expectations are tight or face upward pressure rather than significant upside potential.
Slightly Bearish -10

Amgen is the biggest drag on the Dow Friday

📉 The Dow closed 0.1% lower at 49,599 points.

⚖️ Components remained evenly split between gains and losses.

💊 Significant drops from Amgen weighed heavily on the index.

🍔 McDonald's losses further dragged down the blue-chip gauge.

📱 Apple's strong gains were offset by these declines.

📉 The Dow Jones Industrial Average closed down 52 points, or 0.1%, at 49,599 according to FactSet data.

⚖️ The market index remained roughly split with half of its components in the green and the other half in the red.

💊 Significant losses from Amgen were a major factor weighing on the broader blue-chip gauge.

🍔 Big losses from McDonald's also contributed to dragging down the Dow Jones Industrial Average.

📱 Strong performance from Apple provided an upward boost that was offset by the declines in Amgen and McDonald's.

Bullish Signals
  • Amgen is classified as a Dow Jones Industrial Average component, confirming its status as a blue-chip leader in the financial markets.
  • The stock's presence provided an upward boost that helped offset broader market weakness, with Apple also contributing to the index gains.
Risk Factors
  • Amgen was described as 'the biggest drag on the Dow Friday', indicating significant negative pressure on the broader index.
  • The company suffered 'big losses' alongside McDonald's, contributing to the Dow closing lower by 52 points or 0.1% at 49,599.
Somewhat Bullish +50

/C O R R E C T I O N -- Amgen/ - PR Newswire

✅ Correction notice updates Q1 2026 financial results previously issued via PR Newswire.

🚀 Business strength shown with 16 brands achieving double-digit growth despite patent expirations.

💰 Biosimilars sales totaled $185 million in Q1 2026, an increase from the prior year.

📅 This correction notice updates the April 30, 2026 press release regarding Amgen's first quarter 2026 financial results previously issued via PR Newswire.

📈 CEO Robert A. Bradway stated that Q1 2026 results demonstrate business strength with 16 brands achieving double-digit growth despite patent expirations and increased competition.

💊 The company highlighted its robust pipeline, noting confidence in delivering long-term growth as a new wave of molecules progresses to Phase 3 clinical development.

📉 Non-GAAP financial measures, including free cash flow, were presented alongside GAAP figures with reconciliations available in the attached documentation.

💰 Biosimilars sales totaled $185 million in Q1 2026, up from $171 million in the same period of the prior year.

🔬 Ultra-Rare products include PROCYSBI®, RAVICTI®, ACTIMMUNE®, BUPHENYL®, and QUINSAIR® as categorized in the financial breakdown.

🌍 Product sales details are broken down by specific product and geographic region in the full report released on PR Newswire.

📊 Operating expense analysis covers Research & Development, Selling, General & Administrative costs, total operating expenses, and operating income percentage of product sales.

💧 Cash flow and balance sheet data are presented in billions except for share counts which are provided in millions.

🚀 Key pipeline updates include MariTide (maridebart cafraglutide), BLINCYTO (blinatumomab), IMDELLTRA (tarlatamab), and Xaluritamig (AMG 509).

🤝 Collaboration highlights include TEZSPIRE development with AstraZeneca, AMG 104 research with AstraZeneca, and Xaluritamig pursuant to a collaboration with Xencor.

🧬 Investigational assets listed include YL201 by MediLink, Zocilurtatug pelitecan by Zai Lab Limited, and Etakafusp alfa by Asher Biotherapeutics.

⚠️ Third-party trademarks for Opdivo (Bristol-Myers Squibb), Keytruda (Merck & Co.), and Ocrevus (Genentech) are noted as not belonging to Amgen.

🏢 Amgen maintains its headquarters in Thousand Oaks, California, where it has been a leader in biotechnology innovation for over 45 years.

🧬 The company uses technology and human genetic data to advance medicines treating cancer, inflammatory conditions, rare diseases, heart disease, and obesity.

🏆 Amgen is consistently recognized for innovation and workplace culture, receiving honors from Fast Company and Forbes.

📉 It remains one of the 30 companies comprising the Dow Jones Industrial Average® and continues to operate at the cutting edge of innovation.

Bullish Signals
  • Amgen's first quarter results demonstrate business strength with 16 brands achieving double-digit growth, enabling the company to navigate patent expirations and increased competition.
  • CEO Robert A. Bradway expressed confidence in delivering attractive long-term growth, supported by a new wave of molecules progressing in Phase 3 clinical development.
  • Ultra-Rare products segment shows robust performance with IMDELLTRA/IMDYLLTRA experiencing a change in sales exceeding 100%.
  • The company continues to advance its broad and deep pipeline targeting cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related conditions.
  • Amgen maintains its position as one of the 30 companies comprising the Dow Jones Industrial Average®, highlighting its market stature.
Risk Factors
  • The company acknowledges significant business challenges, noting that growth in 16 brands is occurring while contending with 'expected patent expirations and increased competition,' indicating future revenue headwinds.
  • Biosimilar sales declined from $185 million in Q1 2026 to $171 million in Q1 2025, highlighting competitive pressure on legacy revenue streams.
  • Rare Disease business reported a loss of ($3) million in Q1 2026 compared to a nominal ($1) million loss in the prior year, signaling potential profitability struggles in this therapeutic area.
  • Management reliance on non-GAAP financial measures and adjustments for acquisitions, restructuring, and other items obscures the true GAAP performance and may mask underlying deterioration or one-time costs.
  • The company's future guidance and analysis depend heavily on 'expected patent expirations,' suggesting a known timeline of revenue cliff risks that are not being mitigated fast enough.
Bullish +75

Amgen's Numbers Are Out: Is The Cholesterol Crown In Play? - Investor's Business Daily

💰 Amgen beat Q1 earnings estimates, raising full-year profit and revenue guidance.

💊 Star drug Repatha surged 34% in sales while Osteoporosis drug Prolia dropped significantly.

🌬️ Obesity candidate MariTide advanced to Phase 3 testing with upcoming Type 2 diabetes trials.

📈 Amgen significantly beat first-quarter analyst expectations, with adjusted earnings of $5.15 per share surpassing the $4.77 Street estimate.

💊 Sales of its cholesterol drug Repatha surged 34% to $876 million, well above the projected $828 million.

🦈 Repatha's growth was driven primarily by a 35% volume increase, despite an 8% deduction from estimated sales prices.

⚖️ Repatha maintains its market lead over rival cholesterol injections, as competitor Praluent generated only $245.7 million.

💰 Amgen raised its 2026 guidance slightly on the back of strong Repatha performance.

📉 Adjusted full-year earnings guidance was revised upward to an expected range of $21.70 to $23.10 per share.

💵 Full-year revenue guidance increased modestly to a projected $37.1 billion to $38.5 billion.

📉 Osteoporosis drug Prolia sales fell 34% to $727 million, missing expectations due to competition from biosimilars.

💉 Tepezza, a treatment for thyroid eye disease, showed solid growth with sales jumping 29% to $490 million.

🌬️ Asthma drug Tezspire lagged analyst forecasts, bringing in $343 million compared to an expected $444 million.

⚠️ Despite beating earnings, Amgen stock slipped nearly 3% in after-hours trading and remained below its 50-day moving average.

🧪 Amgen is advancing obesity treatments MariTide and AMG 513, with nine ongoing studies for MariTide.

👩‍⚕️ MariTide has entered Phase 3 testing, indicating the company is nearing potential regulatory filings for an obesity drug.

🔬 The company plans to initiate three new clinical studies for MariTide in patients with type 2 diabetes this year.

📊 Overall Q4 revenue growth of 6% brought total sales to $8.62 billion, exceeding the consensus forecast of $8.58 billion.

Bullish Signals
  • Amgen (AMGN) widely beat first-quarter Street expectations, adjusting earnings up 5% to $5.15 per share versus the consensus of $4.77.
  • Revenue surged in its cholesterol blockbuster Repatha, jumping 34% year-over-year to $876 million, significantly topping projections of $828 million.
  • The company raised its full-year outlook, projecting adjusted earnings of $21.70 to $23.10 per share at the midpoint, an increase of 10 cents from guidance issued three months ago.
  • Full-year sales guidance was also boosted to a range of $37.1 billion to $38.5 billion, expanding from the previous forecast of $37 billion to $38.4 billion.
  • Tepezza, a thyroid eye disease treatment, delivered strong results by growing 29% year-over-year to $490 million, hammering forecasts for $419 million.
  • MariTide, the obesity treatment in late-stage development, is advancing with nine ongoing studies and plans to start three new trials for type 2 diabetes this year.
  • Amgen confirmed that MariTide studies are already in Phase 3 testing, positioning the company close to potential regulatory filings for this obesity drug.
Risk Factors
  • Amgen stock slipped nearly 3% in after-hours trading to $336.82, remaining rangebound beneath its 50-day moving average.
  • Repatha sales growth was driven primarily by volume rather than price, with sales prices falling 7% and only an 8% favorable change from deductions offsetting a 35% volume jump.
  • Amgen's osteoporosis treatment Prolia saw sales tumble 34% to $727 million, widely missing expectations of $841 million due to heightened biosimilar competition.
  • Evenity sales came up short at $562 million, falling below the expected $567 million forecast.
  • The AstraZeneca-partnered asthma treatment Tezspire brought in $343 million, significantly lagging analyst calls for $444 million despite 20% growth.
  • Amgen faces increasing competition in its core cholesterol franchise as Regeneron and Sanofi's Praluent grew 27%, though it still earned less than half of Repatha's revenue.
Somewhat Bullish +50

Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates

📈 Amgen beat EPS estimates by 8.87% and revenues by 1.71%.

✅ The company has outperformed consensus in four consecutive quarters.

⏳ Peer Tarsus expects a loss despite massive revenue growth expectations.

📉 Amgen shares rose 3.3% while the broader sector lags behind.

🔮 Upcoming quarter forecasts show EPS of $5.79 and revenues of $9.45B.

📈 Amgen reported Q1 earnings of $5.15 per share, exceeding the consensus estimate of $4.73 and beating last year's figures of $4.90.

🏆 The company achieved an 8.87% positive earnings surprise compared to the quarterly expectation of $4.76 per share.

📊 Amgen generated Q1 revenues of $8.62 billion, surpassing analyst estimates by 1.71% against a year-ago total of $8.15 billion.

✅ The company has outperformed consensus EPS estimates in all four consecutive quarters reported so far.

📉 Since the start of the year, Amgen shares have gained approximately 3.3%, trailing the S&P 500's 4.2% return.

⚠️ Based on mixed estimate revision trends prior to the report, the stock currently holds a Zacks Rank #3 (Hold).

🔮 Analysts maintain a forward consensus EPS estimate of $5.79 per share for the upcoming quarter with revenues projected at $9.45 billion.

🌍 The broader Medical - Biomedical and Genetics industry rank is in the bottom 41%, suggesting potential underperformance relative to top-ranked sectors.

⏳ Tarsus Pharmaceuticals (TARS), a peer company in the same sector, is yet to release its Q1 results but expects a loss of $0.43 per share.

📈 Tarsus is anticipated to report revenues of $149.52 million, representing a 90.9% increase from the previous year's quarter.

🔄 Recent research indicates a strong correlation between earnings estimate revision trends and near-term stock price movements.

📄 Amgen belongs to the Zacks Medical - Biomedical and Genetics industry which currently faces mixed outlook conditions.

Bullish Signals
  • Amgen reported quarterly earnings of $5.15 per share, surpassing the Zacks Consensus Estimate of $4.73 per share by 8.87%.
  • Revenues reached $8.62 billion for the quarter ended March 2026, exceeding analyst estimates and showing year-over-year growth from $8.15 billion.
  • The company has topped consensus revenue estimates four times over the last four consecutive quarters.
  • Over the past four quarters, Amgen has surpassed consensus EPS estimates on four out of four occasions, demonstrating consistent operational strength.
  • Earnings per share increased to $5.15 compared to $4.90 a year ago, reflecting adjusted growth even when accounting for non-recurring items.
Risk Factors
  • Amgen shares have underperformed the S&P 500 so far this year, gaining only 3.3% compared to the index's 4.2% return.
  • The Zacks Rank for Amgen is currently a #3 (Hold), indicating the stock is expected to perform in line with the market rather than outperforming.
  • The 'Medical - Biomedical and Genetics' industry ranks in the bottom 41% of all Zacks industries, creating a structural headwind for the company.
  • Industry research suggests that top 50% industries outperform the bottom 50% by more than 2 to 1, putting Amgen at a relative disadvantage.
  • Although the quarterly and fiscal year estimates are positive, management commentary on sustainability will be a key variable that could lead to further downside if expectations are not met.
Somewhat Bullish +50

Amgen (AMGN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

📈 Amgen revenue hit $8.62B, beating estimates with a 5.8% year-over-year increase.

💊 Key drugs diverged sharply as Repatha grew while Enbrel and XGEVA declined.

📉 Shares fell -4.3% despite earnings beats, prompting analysts to rate the stock Hold.

📊 Amgen (AMGN) reported Q1 2026 revenue of $8.62 billion, a 5.8% increase year-over-year.

💰 Earnings per share reached $5.15, surpassing the analyst consensus estimate of $4.73 with an 8.87% surprise.

📈 Repatha generated total product sales of $876 million, exceeding estimates by 33.5% year-over-year.

⚠️ Enbrel showed a significant decline in performance with total sales of $320 million compared to a 37.3% drop from the previous year.

📉 Prolia reported total sales of $727 million, reflecting a 33.9% decrease year-over-year despite analyst estimates of $831.86 million.

💊 BLINCYTO demonstrated strong growth in ROW markets with sales of $194 million against an estimate of $118.06 million.

🇺🇸 Nplate showed positive momentum in the U.S. market with revenue of $283 million, up 40.8% from last year.

📉 XGEVA declined in the U.S. region to $228 million, which is -36.7% lower than the same period last year.

📊 Amgen's stock returned -4.3% over the past month compared to the S&P 500's gain of +12.2%.

⚖️ The company holds a Zacks Rank #3 (Hold), suggesting potential performance aligned with the broader market.

🔬 The article highlights various other drugs like Vectibix, KYPROLIS, and Nplate alongside their specific sales figures and estimates.

🌐 Amgen's total revenue beat the consensus estimate of $8.47 billion by 1.71%.

⏱️ Repatha sales in international regions (ROW) rose to $411 million, representing a 31.3% increase from last year.

💻 The article transitions into unrelated promotional content about quantum computing and other stocks like Lightspeed Commerce.

📄 The report is attributed to Zacks Investment Research, which emphasizes earnings estimate revisions as a driver for stock prices.

Bullish Signals
  • Amgen reported revenue of $8.62 billion for Q1 2026, representing a positive 5.8% increase year-over-year.
  • The company beat Wall Street expectations on both fronts, delivering a +1.71% revenue surprise and an impressive +8.87% EPS surprise.
  • Repatha sales in international regions (ROW) surged 31.3% year-over-year to $411 million, significantly exceeding the analyst consensus of $373.03 million.
  • BLINCYTO sales were a standout success story with a massive 100% year-over-year growth and total global sales of $415 million, beating estimates by seven analysts.
  • Nplate revenue grew over 31% year-over-year in both the U.S. and globally, demonstrating strong momentum in this new product segment.
  • Kymirs (Kyprolis) generated $328.67 million in sales, aligning closely with analyst estimates and showing stable demand.
Risk Factors
  • Amgen's stock returned -4.3% over the past month, significantly underperforming the Zacks S&P 500 composite which gained +12.2% during the same period.
  • Product sales for Enbrel- Total were $320 million, missing the seven-analyst average estimate of $426.94 million by approximately $107 million, representing a year-over-year decline of -37.3%.
  • Sales for XGEVA- U.S. ($228 million) fell short of the six-analyst average estimate of $238.6 million and saw revenue drop -36.7% year-over-year to $228 million versus the prior period.
  • Product sales for Prolia- Total reached $727 million, which is below the seven-analyst average estimate of $831.86 million, indicating a -33.9% year-over-year change.
  • XGEVA- Total sales ($411 million) underperformed the seven-analyst average estimate of $389.57 million and experienced a significant -27.4% decline compared to the year-ago quarter.
  • Amgen's shares are currently assigned a Zacks Rank #3 (Hold), suggesting analysts expect the stock to perform in line with the broader market rather than outperform.
Bullish +75

Amgen Q1 Earnings Call Highlights

📈 Top six drivers grew 24%, fueling nearly 70% of total sales.

💊 Repatha, Evenity, and TEPEZZA surged on guideline updates and new data.

⚠️ Guidance raised to $37.1B–$38.5B despite biosimilar erosion and IRS audits.

📈 Amgen reported a strong Q1 with its six key growth drivers growing collectively by 24% and accounting for nearly 70% of total sales.

💊 Repatha sales reached $876 million, up 34%, driven by updated guidelines and positive subgroup data showing reduced cardiovascular events in high-risk patients.

🦴 Evenity sales increased 27% to $562 million globally, holding a 65% share of the U.S. bone builder market with strong uptake in Japan.

💨 TEPEZZA sales climbed 29% to $490 million as endocrinology prescribing grew, supported by new Phase III data for a subcutaneous on-body injector.

🧬 Tepezza's rare-disease portfolio, led by Uplizna which surged 188%, saw total category growth of 25% to $1.2 billion across all approved indications.

📉 Prolia and Xgeva combined sales fell 32% year-over-year to $1.1 billion due to expected erosion from biosimilar competition through 2026.

💉 Innovative oncology portfolio grew 25% to $1.8 billion, highlighted by IMDELLTRA administration at over 1,800 U.S. sites and Bincyto growth.

🧬 Biosimilar sales rose 14% to $835 million, led by Pavblu which contributed $280 million with a prefilled syringe format valued by specialists.

💵 Repatha now has a cash-pay option available for approximately 8,000-9,000 patients at $239/month, though management notes this represents a small portion of volume.

🔬 Chief Scientific Officer Jay Bradner detailed the Phase III MariTide obesity program expansion into long-term maintenance dosing schedules (monthly/quarterly) to reduce treatment burden.

⚠️ Management raised full-year 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS to $21.70–$23.10 despite ongoing IRS audit uncertainties.

🛡️ Executives maintain a disciplined R&D strategy led by MariTide, aiming for products in 2026 to offset patent expirations and competitive pressures.

🗓️ A new Phase III switching study was launched to evaluate patients switching from weekly GLP-1s to MariTide under various dosing intervals.

🇯🇵 TEPEZZA plans additional global launches following its 2025 introduction in Japan, supported by growing prescriber interest and increased endocrinology adoption.

🚀 CEO Robert Bradway reiterated that 2026 is a "springboard year" designed to sustain growth through expanding franchises despite market headwinds.

Bullish Signals
  • Amgen delivered a strong Q1 with six key growth drivers accounting for nearly 70% of sales and collectively growing 24% year-over-year.
  • The rare-disease portfolio surged 25% to $1.2 billion, led by Uplizna which skyrocketed 188% to $262 million driven by strong uptake across all three approved indications.
  • Repatha sales reached $876 million, up 34%, bolstered by positive subgroup analysis showing a 31% reduction in cardiovascular events for high-risk patients with diabetes at the American College of Cardiology meeting.
  • Evenity sales rose 27% to $562 million with U.S. sales increasing 35% and maintaining a dominant 65% share of the U.S. bone builder market.
  • TEPEZZA sales climbed 29% to $490 million, supported by growth in the chronic rhinosinusitis indication and a new Phase III data point for an on-body injector supporting subcutaneous administration.
  • Innovative oncology portfolio sales grew 25% to $1.8 billion, with IMDELLTRA administered at over 1,800 U.S. sites and BLINCYTO sales up 12% to $415 million.
  • Biosimilars revenue increased 14% to $835 million, highlighted by Pavblu delivering $280 million in the quarter due to its prefilled syringe format and supply reliability.
  • Amgen raised full-year 2026 guidance to $37.1–$38.5B in revenues with a non-GAAP EPS target of $21.70–$23.10, signaling management confidence despite potential tax headwinds.
  • The MariTide Phase III program was expanded to include long-term maintenance dosing and a 300-patient switching study, reporting improved tolerability with flexible monthly/8-week/quarterly schedules.
  • Amgen anticipates accelerated pressure from biosimilars remains in line with expectations for Prolia and Xgeva, allowing management to focus resources on high-growth franchises.
Risk Factors
  • Ongoing IRS audits and tax litigation could materially affect future results if adjustments are sustained.
  • Prolia and Xgeva sales declined 32% year-over-year, with Amgen warning of accelerated pressure through the rest of 2026 due to increasing biosimilar competition.
  • TEPEZZA growth was partially offset by a 'burn in channel inventory'.
Slightly Bullish +25

What Are Wall Street Analysts' Target Price for Amgen Stock?

📉 Shares gained 17.1% last year, underperforming the S&P 500's 28.3%.

💰 Q4 EPS of $5.29 and revenue beat forecasts on Feb. 3.

💼 Analyst consensus is "Moderate Buy" with a mean price target of $357.84.

🧬 Amgen Inc. (AMGN) develops and delivers human therapeutics with a market capitalization of $182.4 billion.

📉 Shares underperformed the S&P 500 last year, gaining 17.1% versus the index's 28.3% rise.

📊 In 2026, AMGN is projected to be up 3.3%, while the SPX is expected to rise 4.2%.

💰 On Feb. 3, Q4 results showed adjusted EPS of $5.29 and revenue of $9.9 billion, both beating forecasts.

🔮 Management expects full-year adjusted EPS between $21.60 and $23 with revenue of $37-38.4 billion.

📈 Analysts project fiscal 2026 diluted EPS to grow 1.5% year-over-year to $22.16.

👍 AMGN beat earnings estimates in each of the last four quarters, maintaining a strong earnings surprise history.

💼 Of 36 analysts covering the stock, the consensus rating is "Moderate Buy" with mixed ratings across Strong Buy and Hold categories.

⚠️ Analyst sentiment has cooled slightly compared to three months ago when more analysts gave "Strong Buy" ratings.

🔍 Canaccord Genuity initiated coverage on Apr. 21 with a "Hold" rating and a $366 price target.

💹 The mean analyst price target is $357.84, representing a 5.9% premium to current stock levels.

🚀 The Street-high price target of $432 suggests a potential upside of 27.8% from current pricing.

Bullish Signals
  • Amgen adjusted EPS hit $5.29, beating Wall Street's $4.76 estimate.
  • Shares closed up more than 8% after earnings beat.
  • Revenue reached $9.9 billion, exceeding forecasts of $9.5 billion.
  • Full-year EPS expected between $21.60 and $23.
  • Full-year revenue forecasted in range of $37B to $38.4B.
  • Beaten consensus estimate for four consecutive quarters.
  • 36 analysts rate AMGN with 'Moderate Buy' consensus.
  • Street-high price target is $432, implying 27.8% upside.
Risk Factors
  • Amgen shares gained only 17.1% vs S&P 500's 28.3% rally last year.
  • In 2026, AMGN up 3.3% vs SPX's 4.2% rise on YTD basis.
  • Pharmaceutical ETF PJP gained 26.9%, while Amgen underperformed peer sector.
  • Analyst bullishness has decreased since three months ago.
  • Of 36 analysts, consensus is Moderate Buy with six bearish ratings.
  • Canaccord initiated coverage with Hold rating and $366 price target.
  • Mean price target of $357.84 offers only 5.9% premium to current levels.
Bullish Signals
  • Amgen's adjusted EPS of $5.29 exceeded Wall Street expectations of $4.76, with shares closing up more than 8% on the following trading session.
  • The company reported revenue of $9.9 billion, which beat Wall Street forecasts of $9.5 billion.
  • AMGN expects full-year adjusted EPS in the range of $21.60 to $23, and revenue in the range of $37 billion to $38.4 billion.
  • The company has beaten the consensus estimate in each of the last four quarters, demonstrating a strong earnings surprise history.
  • Among the 36 analysts covering AMGN stock, the consensus is a 'Moderate Buy' based on 13 'Strong Buy' ratings.
  • The Street-high price target of $432 suggests an upside potential of 27.8% from current levels.
Risk Factors
  • Shares of Amgen have underperformed the broader market over the past year, gaining only 17.1% compared to the S&P 500 Index's rally of nearly 28.3%. In 2026, AMGN stock is up 3.3%, compared to the SPX's 4.2% rise on a YTD basis.
  • Amgen's performance lags behind its peers, with the Invesco Pharmaceuticals ETF (PJP) gaining about 26.9% over the past year while AMGN has underperformed relative to this broader pharmaceutical sector benchmark.
  • The analyst configuration is less bullish than three months ago, with fewer analysts suggesting a 'Strong Buy' rating compared to previous sentiment.
  • Among the 36 analysts covering AMGN stock, the consensus is a 'Moderate Buy,' but there are six bearish ratings including two 'Strong Sells', one 'Moderate Sell'.
  • Analyst Canaccord Genuity initiated coverage with a 'Hold' rating and set a price target of $366, implying only modest upside potential.
  • The mean price target of $357.84 represents just a 5.9% premium to AMGN's current price levels, suggesting limited near-term valuation appreciation.
Slightly Bullish +25

What Are Wall Street Analysts' Target Price for Amgen Stock? - Yahoo Finance

📉 Stock gained 17.1% while the S&P 500 rallied 28.3% recently.

💰 Analysts project adjusted EPS between $21.60 and $23 for the full year.

🗳️ Mean price target is $357.84, implying 5.9% upside to current levels.

🏆 Company has beaten earnings estimates for four consecutive quarters in a row.

🧬 Amgen Inc. (AMGN) is a pharmaceutical company with an $182.4 billion market cap, focusing on discovering and delivering human therapeutics based on cellular and molecular biology.

📉 The stock has underperformed the broader S&P 500 Index over the past year, gaining only 17.1% compared to the index's 28.3% rally.

📊 On February 3, AMGN reported Q4 results with adjusted EPS of $5.29 and revenue of $9.9 billion, both exceeding Wall Street estimates.

🔮 Analysts expect full-year adjusted EPS between $21.60 and $23, with a fiscal 2026 diluted EPS growth expectation of 1.5% to $22.16.

🏆 The company has beaten the consensus estimate in earnings for each of the last four quarters, highlighting an impressive earnings surprise history.

🗳️ Among 36 analysts covering AMGN, the consensus rating is a "Moderate Buy," with ratings including 13 "Strong Buys," 18 "Holds," and two "Strong Sells."

📉 The bullish sentiment among analysts has decreased compared to three months ago, when 14 analysts suggested a "Strong Buy" rating.

🔍 Canaccord Genuity initiated coverage on April 21 with a "Hold" rating and a price target of $366, implying an 8.3% upside from current levels.

💰 The mean analyst price target is set at $357.84, representing a 5.9% premium to AMGN's current stock price.

🚀 The street-high price target stands at $432, which suggests a significant upside potential of 27.8% for shareholders.

Bullish Signals
  • AMGN reported Q4 results on Feb. 3, with its shares closing up more than 8% in the subsequent trading session.
  • The company's adjusted EPS of $5.29 exceeded Wall Street expectations of $4.76, demonstrating strong earnings performance.
  • Revenue reached $9.9 billion, beating Wall Street forecasts of $9.5 billion, highlighting robust demand for its therapeutics.
  • AMGN expects full-year adjusted EPS in the range of $21.60 to $23, and revenue in the range of $37 billion to $38.4 billion, indicating solid growth guidance.
  • The stock has beaten the consensus estimate in each of the last four quarters, showcasing a consistent earnings surprise history.
  • With a market cap of $182.4 billion, AMGN focuses on innovating novel medicines based on cellular and molecular biology within human therapeutics.
  • Among 36 analysts covering AMGN stock, 13 have provided 'Strong Buy' ratings, reflecting significant analyst confidence in the company's prospects.
  • The mean price target of $357.84 represents a 5.9% premium to current price levels, offering upside potential for investors.
  • The Street-high price target of $432 suggests an upside potential of 27.8%, indicating bullish sentiment from Wall Street analysts.
Risk Factors
  • Shares of Amgen (AMGN) have underperformed the broader market over the past year, gaining only 17.1% compared to the S&P 500 Index's rally of nearly 28.3%.
  • Despite beating Wall Street expectations recently, the consensus analyst rating is "Moderate Buy" which includes six bearish ratings (one Moderate Sell and two Strong Sells) among 36 analysts.
  • The number of "Strong Buy" ratings decreased from 14 to 13 over the last three months, indicating a softening in bullish sentiment among Wall Street analysts.
  • Analyst Canaccord Genuity initiated coverage with a "Hold" rating and a price target of $366, suggesting limited upside potential compared to peers.
  • Amgen's stock is currently trading below its analyst consensus mean price target of $357.84, implying the stock may still be undervalued despite recent gains.
Neutral +5

Amgen Q1 Preview: What to expect

📅 Amgen reports Q1 results on April 30 after closing bell.

💰 Consensus EPS is projected to decline slightly by 3%.

📈 Revenue expected to grow 5.8% year-over-year to $8.57 billion.

📊 Analysts foresee slight earnings downside despite strong revenue growth.

📅 Amgen (AMGN) is scheduled to report its Q1 earnings results on April 30 after the closing bell.

💰 Analysts project a consensus EPS estimate of $4.77, indicating a nearly 3% decline from the previous period.

📈 Revenue is expected to reach $8.57 billion, representing a 5.8% year-over-year increase.

🏢 The preview article was published by Seeking Alpha on April 29, 2026.

👩‍💼 Nivedita Hazra served as the news editor and author for this earnings preview report.

📊 Market analysts anticipate slight downside pressure on per-share earnings despite revenue growth.

Bullish Signals
  • Amgen (AMGN) projects 6% YoY revenue growth to $8.57B.
  • Top-line increase expected from core segments before April 30 report.
Risk Factors
  • Amgen EPS projected to fall 3% versus $4.77 consensus.
  • Profitability expected to decline despite rising revenue growth.
Bullish Signals
  • Amgen (AMGN) is projected to deliver nearly 6% year-over-year revenue growth of $8.57 billion for Q1.
  • The company anticipates a quarterly top-line increase driven by its core business segments ahead of the April 30 report date.
Risk Factors
  • Amgen is projected to report a nearly 3% fall in its Q1 earnings (EPS), with the consensus estimate at $4.77.
  • The company faces expectations of declining profitability even as revenue grows, creating a potential disconnect between top-line growth and bottom-line performance.
Neutral 0

Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow - StockStory

📅 Amgen announces Q1 earnings tomorrow after beating estimates last quarter with $9.87B revenue.

⏳ Wall Street expects modest 4.3% growth this quarter versus last year's 10% increase.

📉 Stock down 2.9% while biotech sector rose 10.8% monthly and peers like Incyte beat targets.

🔍 Analysts revised estimates upward recently, though Amgen missed revenue expectations multiple times in past years.

🎯 Average price target of $352.73 suggests potential upside if earnings meet expectations.

📅 Amgen (AMGN) is scheduled to announce Q1 earnings results tomorrow afternoon on Thursday.

💰 Last quarter, the company beat revenue expectations with $9.87 billion reported, an 8.6% year-over-year increase.

🚀 Full-year revenue guidance also surpassed analyst estimates during the previous strong quarter.

⏳ Current market expectations for this quarter include a more modest 4.3% year-over-year revenue growth.

📉 This projected growth represents a slowdown compared to the 10% increase recorded in Q1 last year.

🔍 Analysts have increasingly turned bullish, with majority of estimates revised upward over the last 30 days.

⚠️ Despite recent optimism, Amgen has missed Wall Street's revenue estimates multiple times over the past two years.

🏥 In the biotech peer segment, Incyte recently reported results exceeding estimates with 20.9% year-over-year sales growth.

📈 The broader biotechnology sector has seen positive investor sentiment, with share prices up 10.8% on average last month.

📉 Conversely, Amgen's stock is down 2.9% during the same period and currently trades at $338.80 per share.

🎯 The average analyst price target stands at $352.73, indicating potential upside if earnings meet expectations.

Bullish Signals
  • Amgen revenue beat estimates at $9.87B, up 8.6% YoY.
  • Full-year guidance exceeded expectations despite anticipated 4.3% growth.
  • Analysts revised revenue estimates upward over the last 30 days.
  • Stock trades at $338.80 below $352.73 average target, showing upside.
Risk Factors
  • Amgen down 2.9% this month while peers gained 10.8%.
  • Expected revenue growth slows from 10% to just 4.3% year-on-year.
  • Missed Wall Street estimates twice in the last two years.
  • Bullish analysts may face harsh reality check if earnings miss.
Bullish Signals
  • Amgen beat analysts' revenue expectations last quarter with revenues of $9.87 billion, representing an impressive 8.6% year-over-year increase.
  • The company provided full-year revenue guidance that exceeded analysts' expectations despite the market anticipating only a 4.3% growth.
  • Analysts covering Amgen have grown increasingly bullish, with the majority of revenue estimates seeing upward revisions over the last 30 days.
  • Amgen currently trades at $338.80, which is below its average analyst price target of $352.73, indicating positive upside potential ahead of earnings.
Risk Factors
  • Amgen is down 2.9% over the last month while its peers in the biotechnology segment have averaged a 10.8% gain, underperforming the broader industry trend.
  • The market expects Amgen's revenue growth to slow significantly from the 10% increase recorded last year to just 4.3% year on year this quarter.
  • Amgen has missed Wall Street's revenue estimates multiple times over the last two years, despite having beaten them in the most recent quarter.
  • Analysts have grown increasingly bullish with majority upward revisions over the last 30 days, which could lead to a harsh reality check if current earnings do not meet elevated expectations.
Neutral 0

Wealthfront Advisers LLC Has $26.93 Million Stock Position in Amgen Inc. $AMGN - MarketBeat

🚫 Unable to retrieve article content due to missing main text.

⚠ Source website requires JavaScript and cookies for access.

❌ No financial details or stock positions could be extracted.

🚫 Unable to retrieve article content due to missing main text, only security verification message.

⚠️ Source website requires JavaScript and cookies for access; summary cannot be generated from available data.

❌ No financial details or stock position information could be extracted from the provided input.

Bullish Signals
  • Wealthfront Advisers holds $26.93M in Amgen Inc. ($AMGN), signaling institutional confidence.
  • Major financial advisors show continued interest in Amgen's growth potential.
Risk Factors
  • No negative information found due to security verification message. No financial data.
  • Article shows only website security challenge. No stock analysis provided.
Bullish Signals
  • MarketBeat is reporting on Wealthfront Advisers LLC holding a $26.93 million stock position in Amgen Inc. ($AMGN), indicating institutional confidence in the company.
  • The specific disclosure of Wealthfront's investment stake highlights continued interest from major financial advisors in Amgen's growth potential.
Risk Factors
  • No negative information was found in the article content provided, as it only displayed a security verification message and no financial data or risks.
  • The article snippet shows only a website security challenge with JavaScript/cookies disabled, offering no actual stock analysis or downside catalysts for Amgen.
Neutral 0

Comerica Bank Has $50.76 Million Stake in Amgen Inc. $AMGN - MarketBeat

⚠ Comerica Bank holds a $50.76 million stake in Amgen Inc. (AMGN).

📊 Exact ownership percentage and share count remain unspecified.

🔒 Technical restrictions prevent access to detailed investment data on the source site.

⚠️ Comerica Bank holds a $50.76 million stake in Amgen Inc. (AMGN) according to MarketBeat reporting.

📊 The article does not specify the exact percentage ownership or the number of shares held by Comerica Bank.

💼 No additional details about the purpose or history of the investment are provided in the available text.

🔒 Technical verification messages indicate security measures preventing full access to detailed financial data on the source website.

Risk Factors
  • No substantive AMGN news found.
Risk Factors
  • The provided content does not contain any substantive news article about Amgen Inc. (AMGN).
Bearish -50

Wall Street Zen Downgrades Amgen (NASDAQ:AMGN) to Hold - MarketBeat

🛑 Wall Street Zen downgrades Amgen to Hold status.

📉 Analysts neutralize recent acquisition-driven stock gains.

⚠ Valuation concerns linger amid high debt levels and portfolio risks.

📊 Stock outperforms peers but faces earnings uncertainty.

🛑 Wall Street Zen has downgraded Amgen (NASDAQ:AMGN) from Buy/Outperform to Hold status.

📉 The upgrade is likely aimed at neutralizing the positive price impact following the recent acquisition news.

🤔 Analysts maintain a cautious outlook given the valuation concerns surrounding the company's large biotech portfolio.

📊 The stock has been performing above peer averages but faces potential challenges from high debt levels.

⚠️ Investors should be aware of upcoming quarterly earnings reports that may affect the Hold rating further.

Risk Factors
  • Analysts downgraded Amgen to Hold.
  • Downgrade signals concern over near-term upside.
Bullish Signals
  • No positive content found in the provided text.
Risk Factors
  • Wall Street analysts initiated a downgrade on Amgen (NASDAQ:AMGN) from Buy/Outperform to Hold, signaling reduced investor confidence.
  • A downgrade by Wall Street typically implies concerns about the stock's near-term upside potential and may suggest deteriorating fundamentals compared to prior expectations.
Neutral -5

Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade

📉 Amgen stock fell 1.17% to $344.55 despite S&P 500 gains.

📅 Earnings scheduled for April 30, 2026, with projected EPS of $4.75.

💰 Net sales expected at $8.49 billion, a 4.16% year-over-year increase.

⚖ Forward P/E ratio of 15.72 trades below the industry average of 21.28.

📉 Amgen stock closed at $344.55, dropping 1.17% despite the S&P 500 rising 0.8%.

📈 The biotech leader has lost 1.29% over the past month, underperforming both the Medical sector and the broader market.

📅 Earnings are scheduled for release on April 30, 2026, with analysts projecting $4.75 per share in EPS.

📊 Expected earnings represent a 3.06% year-over-year decline compared to the previous period.

💰 Analysts forecast net sales of $8.49 billion for the upcoming quarter, marking a 4.16% increase.

🧮 Full-year consensus estimates project earnings of $22.18 per share and revenue of $37.81 billion.

📉 Recent EPS projection changes show a 0.66% decrease in consensus over the last 30 days.

⚖️ Amgen's current Forward P/E ratio is 15.72, which trades at a discount to the industry average of 21.28.

📏 The stock carries a PEG ratio of 3.64, significantly higher than the industry average of 1.49.

🔝 Amgen currently holds a Zacks Rank of #3 (Hold), positioned as neither a strong buy nor sell.

🏭 The company belongs to the Medical - Biomedical and Genetics industry, ranked in the top 40% of all sectors.

Bullish Signals
  • Amgen's April 30 earnings expected to show 4.16% revenue growth to $8.49B.
  • Full-year estimates forecast earnings of $22.18 with revenue of $37.81B.
  • Revenue and earnings show positive year-over-year growth of +2.88% and +1.56%.
  • Amgen trades at Forward P/E of 15.72, below industry average of 21.28.
  • Industry rank of 96 places Amgen in top 40% of all industries.
Risk Factors
  • Stock declined 1.17% vs S&P 500 gain of 0.8%.
  • Company depreciated 1.29% while market gained 8.11%.
  • Earnings projected to decline 3.06% year-over-year by April 2026.
  • EPS projections fell 0.66% in past 30 days.
  • Held Zacks Rank #3 vs top-rated #1 or #2 strong buy.
  • PEG ratio of 3.64 exceeds industry average of 1.49.
  • Forward P/E of 15.72 amid earnings contraction risks.
Bullish Signals
  • Amgen's upcoming earnings report on April 30, 2026, is expected to show revenue growth of 4.16%, with analysts projecting net sales of $8.49 billion, which would be a year-over-year increase.
  • The Zacks Consensus Estimates forecast full-year earnings of $22.18 per share and revenue of $37.81 billion, indicating positive growth of +1.56% and +2.88%, respectively, compared to the previous year.
  • Amgen is trading at a Forward P/E ratio of 15.72, which represents a discount compared to its industry average Forward P/E of 21.28, suggesting potential valuation upside.
  • The Medical - Biomedical and Genetics industry in which Amgen operates holds a Zacks Industry Rank of 96, positioning it in the top 40% of all industries according to Zacks Investment Research.
  • Research indicates that industries with higher Zacks ranks outperform lower-rated groups significantly, with top 50% rated industries outperforming the bottom half by a factor of 2 to 1.
Risk Factors
  • Amgen's stock declined by -1.17% in the latest session, underperforming the S&P 500 which gained 0.8%.
  • The company has depreciated by 1.29% over the past month while the broader market saw an 8.11% gain in the S&P 500.
  • Analysts expect upcoming earnings on April 30, 2026 to show a year-over-year earnings decline of 3.06%.
  • The consensus EPS projection for Amgen has moved 0.66% lower within the past 30 days, indicating negative short-term momentum.
  • Amgen currently holds a Zacks Rank of #3 (Hold), which is below the top-rated #1 or #2 categories associated with strong buy ratings.
  • The company's PEG ratio stands at 3.64, which is significantly higher than the industry average PEG ratio of 1.49 for the Medical - Biomedical and Genetics industry.
  • Amgen trades at a Forward P/E of 15.72, yet investors should note that this valuation metric must be viewed in the context of potential earnings contraction risks.
Neutral 0

Directional Asset Management Makes New $2.41 Million Investment in Amgen Inc. $AMGN - MarketBeat

Bullish Signals
  • Directional Asset Management added a $2.41M stake in Amgen.
  • Institutional investors show strong confidence in Amgen's future.
  • Fresh capital inflows signal robust bullish market sentiment.
Risk Factors
  • Content inaccessible due to JavaScript verification errors.
  • No usable information on Amgen Inc. analysis.
Bullish Signals
  • Directional Asset Management has initiated a new $2.41 million investment in Amgen Inc., demonstrating institutional confidence in the company's prospects.
  • The marketbeat.com article highlights fresh capital inflow, which can signal strong bullish sentiment from asset managers.
Risk Factors
  • Article content is inaccessible due to JavaScript verification errors, preventing any actual analysis of Amgen Inc. $AMGN financial performance or risks.
  • No substantive information about directional asset management investment or specific downside catalysts for $AMGN could be extracted from the provided text.
Slightly Bullish +25

Amgen Announces CTO Retirement and Strategic Leadership Realignment

🎯 David M. Reese retires as CTO on June 30, 2026 after championing AI adoption.

🔄 Leadership roles realigned under convergent innovation strategy for R&D and technology integration.

📉 Financial constraints include high leverage despite reasonable P/E ratio of ~23.8x.

📅 Amgen announced on April 22, 2026 that David M. Reese will retire as CTO effective June 30, 2026.

🔬 Dr. Reese, who led R&D from 2018 to 2023, will stay on as executive vice president until his retirement date.

🤖 Reese championed early adoption of artificial intelligence across the business during his tenure.

🔄 Amgen will redistribute CTO responsibilities starting June 1, 2026 under its "convergent innovation" strategy.

👨‍💼 James Bradner is appointed executive vice president of Research and Development, Artificial Intelligence and Data.

🛡️ Sean Bruich becomes senior vice president and chief technology officer to lead the technology integration efforts.

🌐 Murdo Gordon's role expands to executive vice president of Amgen Global Markets and Policy.

💉 Paul Burton is confirmed as senior vice president and chief medical officer following the leadership realignment.

🎯 These changes aim to align R&D, AI, data, medical, and commercial functions with advanced technologies.

💰 Analyst consensus rates AMGN stock a Hold with a $335.00 price target according to TipRanks.

⚡ Spark's AI Analyst rates AMGN as an Outperform due to strong technical strength and defined 2026 guidance.

📉 Financial risk from high leverage and recent decline in free cash flow remain key constraints for investors.

💵 The company has a ~23.8 P/E ratio, which analysts view as reasonable but not cheap at current valuation.

📈 AMGEN provides a ~2.6% dividend yield to shareholders.

🏢 Amgen is a Dow Jones Industrial Average and Nasdaq-100 Index member headquartered in Thousand Oaks, Calif.

Bullish Signals
  • Amgen implements leadership changes effective June 1, 2026.
  • James Bradner becomes executive vice president of R&D, AI, and Data.
  • Sean Bruich appointed senior vice president and chief technology officer.
  • Paul Burton confirmed as senior vice president and chief medical officer.
  • Murdo Gordon expands remit to executive vice president of Global Markets and Policy.
  • Leadership moves align functions with advanced healthcare technologies.
  • Amgen strengthens competitive positioning and operational focus.
  • AMGN receives positive AI Analyst spark score on earnings-call outlook.
  • Amgen maintains a 2.6% dividend yield for investors.
  • Company advances deep medicine pipeline using AI research.
Risk Factors
  • CTO David M. Reese departed.
  • Free cash flow declining despite reasonable P/E.
  • Stock overvalued at 23.8 P/E ratio.
Bullish Signals
  • Amgen will redistribute CTO responsibilities and implement strategic leadership changes effective June 1, 2026, including appointing James Bradner as executive vice president of Research and Development, Artificial Intelligence and Data.
  • Sean Bruich is named senior vice president and chief technology officer to deepen the integration of science and technology and support Amgen's convergent innovation strategy.
  • Paul Burton is confirmed as senior vice president and chief medical officer, while Murdo Gordon's remit expands to executive vice president of Amgen Global Markets and Policy.
  • These leadership moves are intended to better align R&D, AI, data, medical and commercial functions with the growing use of advanced technologies across the healthcare ecosystem.
  • Amgen is reinforcing its competitive positioning and operational focus on technology-driven drug discovery and patient engagement through these strategic realignments.
  • AMGN scores positively overall according to Spark's AI Analyst, led by strong technical strength and supportive earnings-call outlook with defined 2026 guidance.
  • Amgen maintains a ~2.6% dividend yield which partially offsets financial considerations for investors.
  • The company continues to advance a broad and deep pipeline of medicines while integrating artificial intelligence and other advanced technologies into its research and commercial operations.
Risk Factors
  • The departure of CTO David M. Reese represents a loss of leadership for the company's chief technology officer role.
  • A recent decline in free cash flow poses financial risk despite a reasonable P/E ratio of approximately 23.8.
  • Valuation constraints remain evident as the stock trades at a ~23.8 P/E, which is considered not cheap given current conditions.
Neutral 0

AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill

📉 Stock down 2.44% this month but up 22.69% yearly, trading at $344.55 USD.

💰 Beat Q4 EPS and revenue expectations by 9.56% and 2.11% respectively.

💵 Offers 2.89% dividend yield with $21.85 non-GAAP EPS over last twelve months.

🧬 Biotechnology leader operates in human therapeutics with $185.95 billion market cap.

🎯 Analyst price target of $360.85 suggests potential 4.73% growth next year.

📉 Stock price is currently $344.55 USD, representing a -1.17% drop in the last trading session and -2.44% decline over the past month.

📈 The stock has increased by 22.69% over the past year but received a low technical rating of 2 out of 10 from ChartMill.

🏅 Fundamental rating is assigned 5 out of 10, indicating excellent profitability paired with concerns regarding financial health.

📊 In Q4 results reported on February 2, 2026, the company beat EPS expectations by 9.56% and revenue expectations by 2.11%.

📈 Analysts project an average price target of $360.85 USD, suggesting a potential 4.73% price increase in the next year.

💰 The company offers a dividend yield of 2.89% with a current yearly dividend amount of $9.01.

📈 EPS growth is expected to be 4.51% and revenue growth 4.12% for the upcoming fiscal year.

💵 Non-GAAP Earnings per Share over the trailing twelve months were $21.85, reflecting a 10.24% increase from the prior year.

🧬 Amgen is a biotechnology company headquartered in Thousand Oaks, California, employing 31,500 full-time staff.

💊 Key marketed products include ENBREL, Repatha, Neulasta, and Parsabiv among others targeting unmet medical needs.

🏢 The company operates in the human therapeutics segment with a focus on high-value diseases.

🎯 CEO Robert A. Bradway leads the organization which discovered and develops human therapeutics.

💰 Market capitalization stands at $185.95 billion, classifying AMGN as a Large Cap stock.

Bullish Signals
  • EPS of $5.29 beat estimates by 9.56%; revenue of $9.87B up 2.11%.
  • Price gained 22.69% this year, outperforming 60.11% of all stocks.
  • Analysts project 4.51% EPS growth and 4.12% revenue growth next year.
  • Stock offers a 2.89% dividend yield with $9.01 yearly payout.
  • Amgen focuses on human therapeutics for tough diseases via key drugs like ENBREL.
  • CEO Robert A. Bradway leads 31,500 employees in a large-cap biotech firm.
  • Market cap of $185.95B ensures stability in the biotechnology industry.
Risk Factors
  • Stock down 1.17% today, -2.44% this month.
  • Chart assigns poor technical rating of 2/10.
  • Analysts question overall financial health despite profits.
  • Only 4.73% price target increase expected yearly.
  • Sluggish revenue growth forecast at 4.12%.
  • Large 185.95B market cap risks high valuation.
Bullish Signals
  • AMGN reported an EPS of 5.29 and revenue of 9.87B on February 2, 2026, beating both EPS expectations by 9.56% and revenue expectations by 2.11%. The company's strong fundamentals were recognized with a 5/10 fundamental rating from ChartMill.
  • The stock has shown solid long-term growth with a price increase of 22.69% over the past year, outperforming 60.11% of all stocks in the market.
  • Analysts project positive future growth with an expected EPS increase of 4.51% and revenue growth of 4.12% for the next year.
  • The stock offers an attractive dividend yield of 2.89% with a yearly dividend amount of 9.01, providing regular income to shareholders.
  • Amgen operates in a high-growth sector focusing on human therapeutics for tough diseases with a large portfolio including ENBREL, Repatha, Otezla, and BLINCYTO.
  • The company is led by CEO Robert A. Bradway and employs 31,500 full-time employees, demonstrating substantial operational scale.
  • With a market capitalization of 185.95 billion USD, AMGN is classified as a large-cap stock, indicating stability in the biotechnology industry.
Risk Factors
  • The stock price is down -1.17% today and has decreased by -2.44% over the past month, indicating near-term weakness.
  • ChartMill assigns a poor technical rating of 2 / 10 to AMGN, signaling significant bearish sentiment from analysts.
  • Despite excellent profitability metrics, there are explicit concerns raised regarding the company's overall financial health.
  • Analyst price targets imply only a modest 4.73% expected increase in stock price over the next year based on current trading levels.
  • Revenue growth is forecast to be sluggish at just 4.12% for the coming year, suggesting limited expansion momentum.
  • The company operates with a large market capitalization of 185.95B USD, which may make it susceptible to high valuation risks if earnings miss.
Slightly Bullish +25

Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

📉 Insiders sold $4.1M in shares with zero purchases over the last year.

💰 Execs like Gordon sold slightly below current market prices totaling millions.

⚠ Zero insider buying combined with selling signals caution despite company profitability.

📉 Multiple Amgen insiders have offloaded shares over the past year, totaling US$4.1 million in sales.

🏢 The largest single insider sale was by Executive Vice President Murdo Gordon, who sold US$2.3m worth of stock.

💰 Murdo Gordon sold his shares at US$337 per share, which is slightly below the current market price of US$346.

📊 In recent months, Chief Accounting Officer Matthew Busch dumped an additional US$376k worth of shares without any accompanying purchases.

❌ Amgen insiders recorded zero stock purchases over the last twelve months and the last three months combined.

🤝 Insiders collectively own only 0.2% of Amgen's shares, holding approximately US$311m in total value based on recent pricing.

⚠️ While insider selling is not always definitive, the combination of no buying activity and sales below current price signals caution.

📈 Despite the negative insider sentiment, analysts note that Amgen remains profitable and growing, which mitigates some concern.

🕸️ The article highlights a single specific warning sign regarding insider transactions before investors consider purchasing shares.

🔍 Open market and private direct interest transactions are tracked, but derivative trades and indirect interests are excluded from the analysis.

Bullish Signals
  • Amgen stays profitable while growing.
  • Strong insider ownership of 0.2% aligns management.
  • Largest sale was just 19% of holdings.
  • Transactions exclude derivative strategies for flexibility.
Risk Factors
  • Insiders sold US$3.476m of shares last year without buying back any.
  • Gordon sold shares at US$337 while the current price is US$346.
  • Amgen insiders own only 0.2% of the company, showing weak alignment.
Bullish Signals
  • Amgen remains profitable and growing, which alleviates concerns about the recent insider selling activity.
  • The company maintains a strong insider ownership base of 0.2%, indicating that management is incentivized to focus on long-term shareholder interests.
  • Recent sales by insiders were only partial holdings; for instance, the largest single sale represented just 19% of Murdo Gordon's total holding.
  • Insider transactions account for only open market and private dispositions, excluding derivatives which might offer additional strategic flexibility.
Risk Factors
  • Multiple insiders, including Executive Vice President Murdo Gordon and Chief Accounting Officer Matthew Busch, have sold shares totaling US$3.476m in the last year without any corresponding purchases, signaling potential lack of confidence.
  • Insider sales often occur at prices below the current market value; for example, Murdo Gordon sold US$2.3m worth of shares at US$337 per share, slightly below the current price of US$346, suggesting insiders may consider the stock less valuable than the market does.
  • Amgen insiders currently own only 0.2% of the company, indicating weak alignment with shareholders and minimal incentive for management to prioritize long-term stock growth over other interests.
Somewhat Bullish +45

Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings

💉 Amgen's TEPEZZA Phase 3 trial showed 77% response vs 19.6% placebo with new subcutaneous injector convenience.

📈 Guggenheim raised price target to $351 while maintaining Neutral rating ahead of April 30 earnings release.

⚠ Some analysts favor AI stocks over Amgen despite company's undervalued Dow component status and positive safety profile.

📈 Guggenheim raised its price target on Amgen Inc. (AMGN) from $347 to $351, citing an updated financial model ahead of earnings.

⚖️ The firm maintains a Neutral rating on AMGN while acknowledging the stock's potential as an undervalued Dow component.

📊 First-quarter results are expected to be released after market close on April 30, following Guggenheim's model update.

💉 Amgen announced positive Phase 3 trial results for TEPEZZA in patients with moderate-to-severe active thyroid eye disease on April 6.

🎯 The trial achieved its primary endpoint with a 77% proptosis response rate compared to 19.6% for placebo over 24 weeks.

👁️ Patients using the new subcutaneous injector showed an average mean eye bulge reduction of -3.17 mm versus -0.80 mm for placebo.

🔬 Secondary endpoints were also met, including improvements in diplopia outcomes, disease activity scores, and quality-of-life measures.

⚕️ Safety findings were consistent with the known intravenous formulation profile, featuring mainly mild-to-moderate injection site reactions.

➡️ The subcutaneous delivery system offers a more convenient administration option compared to the established intravenous formulation.

🏢 Amgen is a leading global biotechnology company focused on oncology, cardiovascular disease, inflammation, bone health, and rare diseases.

⚠️ Some analysts suggest AI stocks offer greater upside potential with less downside risk compared to AMGN currently.

📰 TheFly reported the analyst action and trial results as part of broader coverage on biotech and undervalued stocks.

Bullish Signals
  • Guggenheim raised price target to $351 ahead of Q4 earnings.
  • TEPEZZA Phase 3 trial met primary endpoint with 77% response rate.
  • Clinical trial showed improvements in diplopia and quality-of-life measures.
  • Subcutaneous delivery offers convenient administration comparable to IV formulation.
  • Safety profile remains mild with no treatment discontinuations.
  • Amgen continues innovating across oncology, cardiovascular, and rare diseases.
Risk Factors
  • Guggenheim kept Neutral rating despite raising price target.
  • Analysts update model before Q1 earnings on April 30.
  • AI stocks offer better upside and lower risk than AMGN.
  • Competitive concerns outweigh explicit risks at present.
Bullish Signals
  • Guggenheim increased Amgen's price target from $347 to $351, reflecting updated optimism ahead of the company's first-quarter earnings expected after market close on April 30.
  • Amgen announced positive Phase 3 results for TEPEZZA using a subcutaneous on-body injector, achieving its primary endpoint with a 77% proptosis response rate versus 19.6% for placebo over 24 weeks.
  • The clinical trial for TEPEZZA demonstrated significant improvements in diplopia outcomes, disease activity scores, quality-of-life measures, and overall responder rates with statistically significant benefits.
  • The subcutaneous delivery system offered a more convenient administration option while maintaining strong clinical performance comparable to the established IV formulation.
  • Amgen's safety profile remained consistent with mild-to-moderate injection site reactions and no treatment discontinuations, indicating favorable risk management for this therapy.
  • As a leading global biotechnology company, Amgen continues to innovate in oncology, cardiovascular disease, inflammation, bone health, and rare diseases using advanced biologics and genetic science.
Risk Factors
  • Guggenheim maintained a Neutral rating on Amgen Inc. (AMGN) despite increasing the price target, indicating uncertainty about future upside potential.
  • The firm is updating its financial model ahead of first-quarter results expected after market close on April 30, suggesting that upcoming earnings could introduce volatility or disappointment.
  • Analysts argue that certain AI stocks offer greater upside potential and carry less downside risk compared to AMGN, reflecting competitive concerns in the investment landscape.
  • There are no significant risks explicitly highlighted beyond analyst preference for AI exposure over biotech investments at present.